Repligen Corporation ($RGEN) Stock Forecast: Down 4.0% Today

What is Repligen Corporation?

Introduction to RGEN and Market Movement: Repligen Corporation (RGEN) is a specialized life-science tools provider, focusing on supplying technologies for biologic drug manufacturing. Today, RGEN experienced a strong bearish movement in the market.

Why is Repligen Corporation going down?

RGEN stock is down 4.0% on Jun 22, 2026 14:40

• The bearish movement in RGEN's stock price could be attributed to the softened enthusiasm for life sciences tools in the market, despite offering bullish Q1 guidance. This indicates a broader sentiment shift impacting the sector.
• Positive outlook on Repligen's future and anticipation of improved sentiment in Q2 may suggest that the current decline is a short-term market correction rather than a reflection of the company's long-term prospects.
• The technical analysis indicating a "Strong Buy" consensus may conflict with the bearish movement, highlighting potential discrepancies between market sentiment and underlying technical indicators.
• While RGEN's revenue breakdown shows a strong performance in filtration products and significant contributions from different regions, market dynamics and sector concerns seem to have overshadowed these positive aspects in today's trading session.

RGEN Price Chart

RGEN Technical Analysis

RGEN News

Repligen Stock - Long-term strategy and bioprocessing niche

This article focuses on Repligen (US7607591002), a specialized life-science tools provider, and its long-term strategy in the bioprocessing market. It highlights the company's business model, which centers on supplying technologies for biologic drug manufacturing, positioning it as a "picks-and-shovels" supplier to the growing biologics market. The article also discusses Repligen's growth logic, its approach to scale through organic development and acquisitions, and the risk factors inherent in its business model, such as exposure to biopharma capital spending cycles and competition.

https://www.ad-hoc-news.de/boerse/news/ueberblick/repligen-stock-long-term-strategy-and-bioprocessing-niche/69592596

Repligen Corporation (RGEN) Slid on Softened Enthusiasm for Life Sciences Tools

Repligen Corporation (RGEN) saw its stock slide due to a softened enthusiasm for life sciences tools, despite offering bullish Q1 guidance and having no exposure to NIH funding slowdowns. Osterweis Capital Management, which holds RGEN, attributed the sector's concerns to a slowdown in NIH purchasing but remains positive on Repligen's outlook and anticipates improved sentiment in Q2. While Repligen's one-month return was positive, the broader challenges in the life sciences sector impacted its Q1 performance within the fund's portfolio.

https://finance.yahoo.com/markets/stocks/articles/repligen-corporation-rgen-slid-softened-124847557.html

RGEN Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for Repligen Corp (RGEN), indicating a "Strong Buy" consensus based on various technical indicators. While overall sentiment is strong buy, the stock is trading below its 200-day moving average. The analysis details momentum indicators, support and resistance levels, and moving average signals to help investors understand its current market position.

https://intellectia.ai/en/stock/RGEN/technical

Repligen Corp (RGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed breakdown of Repligen Corp's (RGEN) revenue by business segment and geographical region, updated as of April 6. For FY2025, filtration products contributed the largest share of revenue, followed by chromatography products, protein products, and process analytics products. Geographically, North America accounted for the largest portion of revenue, with Europe and APAC/Other regions also making significant contributions.

https://www.tradingkey.com/markets/stocks/nasdaq-rgen/revenue

Repligen Corp (RGEN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Repligen Corp (RGEN), listing major institutional holders like BlackRock, T. Rowe Price, and Vanguard. It breaks down shareholder types by proportion and provides a historical overview of institutional shareholding data from Q4 2023 to Q1 2026, including changes in shares held. The report also identifies related ETFs that hold RGEN stock.

https://www.tradingkey.com/markets/stocks/nasdaq-rgen/ownership

Trending Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.2% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 5.4% Today

Netflix Inc. ($NFLX) Stock Forecast: Down 5.1% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Up 7.0% Today

10x Genomics, Inc. ($TXG) Stock Forecast: Down 5.1% Today

Cognizant Technology Solutions Corporation ($CTSH) Stock Forecast: Down 5.4% Today

Bumble Inc. ($BMBL) Stock Forecast: Down 5.4% Today

MicroVision Inc. ($MVIS) Stock Forecast: Up 5.1% Today

Virgin Galactic Holdings Inc ($SPCE) Stock Forecast: Down 5.2% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Up 5.7% Today

Repligen Corporation Price History

21.04.2026 - RGEN Stock was up 5.0%

• Repligen's strong bullish movement can be attributed to the positive investor sentiment surrounding the company's recent focus on ESG progress and sustainability initiatives, as highlighted in its 2025 Corporate Sustainability Report.
• The company's commitment to maintaining 100% renewable electricity in its manufacturing operations and reducing global water withdrawals by 14% has likely resonated well with investors, positioning Repligen as a leader in sustainable practices within the bioprocessing tools industry.
• The stock's 4.2% increase and undervaluation according to GuruFocus's GF Value™ may have attracted value investors looking for growth opportunities, despite concerns raised about the P/E ratio and insider selling. This mix of positive sustainability news and potential value investment opportunities could have been key drivers behind today's bullish market movement for Repligen Corp.

09.05.2026 - RGEN Stock was up 6.0%

• The stock's upward momentum is linked to it being perceived as undervalued, supported by a strong GF Score of 79/100, signaling solid growth and financial health.
• Despite a recent decline post-earnings, Repligen's Q1 2026 performance outpaced expectations, showcasing robust revenue growth and an emphasis on expanding margins in its bioprocessing segment.
• The company's shift towards more lucrative bioprocessing sectors and global markets, coupled with initiatives like establishing a new Training & Innovation Center, have likely bolstered investor trust in its future prospects.
• While certain concerns like insider selling and customer concentration risks linger, Repligen's optimistic financial outlook and growth direction appear to be the driving forces behind today's bullish market movement.

04.05.2026 - RGEN Stock was up 5.0%

• Repligen's stock price rose significantly today by 8.45% to reach USD 126.56, surpassing the S&P 500's performance.
• This uptrend is linked to Wolfe Research's initiation of coverage on Repligen with an outperform rating and a target price of $145.00, reflecting optimism about the company's prospects.
• Moreover, the overall surge in the medical instruments and supplies industry, lifting Repligen's stock by 6.2%, indicates a sector-wide positive movement affecting multiple firms simultaneously.
• Despite challenges, Repligen's recent strong financial results in Q1 2026, coupled with analyst endorsements, are likely factors contributing to the bullish market sentiment.

04.05.2026 - RGEN Stock was up 5.2%

• Repligen's strong Q1 2026 performance, with revenue growth and margin focus, has impressed analysts and investors, leading to a bullish movement in the stock.
• Analysts are optimistic about Repligen's future prospects, with coverage initiating an outperform rating and a price target of $145.00, based on the company achieving growth targets and margin improvements.
• Despite some concerns about overvaluation, the positive momentum from recent financial results and analyst coverage has driven investor confidence in Repligen's long-term investment narrative.
• The company's strategic pivot towards higher-value bioprocessing areas and global markets, as well as its strong balance sheet and cash generation, have positioned it well for future growth and expansion, contributing to the bullish market movement.

24.03.2026 - RGEN Stock was up 5.9%

• Repligen Corporation's (RGEN) stock witnessed a positive movement despite a recent 52-week low.
• The CEO's sale of company shares under a 10b5-1 plan initially sparked concerns, but the market response appears favorable, potentially interpreted as a strategic decision.
• Favorable ratings and increased price targets from analysts, in addition to the anticipation of the upcoming financial results announcement, likely contributed to the optimistic sentiment surrounding RGEN.
• The market seems hopeful about the company's growth prospects, particularly following strong Q4 2025 earnings and the establishment of a new training center in the Netherlands, signaling global expansion.

29.03.2026 - RGEN Stock was down 5.2%

• The company is expected to report a decline in earnings for the quarter, with analysts projecting a decrease in earnings per share despite higher revenues. This negative outlook likely contributed to the bearish movement in the stock.
• An insider share sale by CEO Olivier Loeillot, along with significant sales by multiple executives over the past six months, has raised concerns among investors and added to the negative sentiment surrounding the stock.
• Despite a recent gain in share price, Repligen (RGEN) has seen a significant drop over the past year, reaching a 52-week low. The company's undervaluation, coupled with insider selling and earnings uncertainties, may have intensified the selling pressure on the stock.

28.04.2026 - RGEN Stock was up 5.1%

• Today's bullish movement in RGEN's stock can be attributed to several factors:
• The release of Repligen's 2025 Corporate Sustainability Report highlighting its commitment to ESG principles and innovation likely resonated well with investors, signaling a strong long-term growth trajectory.
• The upcoming presentation at the William Blair 46th Annual Growth Stock Conference by the company's CEO further fueled optimism among analysts and investors, leading to increased buying activity.
• The combination of positive developments, including operational expansions and earnings updates, has created a favorable sentiment around Repligen, driving the stock price higher.
• The focus on sustainability, coupled with participation in key industry events, positions Repligen as a leading player in the bioprocessing market, attracting investor attention and contributing to today's bullish market movement.

13.04.2026 - RGEN Stock was down 5.5%

• The bearish movement in RGEN's stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• The news of the Chief Product Officer having shares withheld for tax obligations and a director exercising stock options might have raised concerns about insider transactions, leading to a negative sentiment in the market.
• Despite the positive financial outlook provided by Repligen, investors may be cautious due to uncertainties in the broader market or industry trends, contributing to the downward pressure on the stock.
• Participation in the upcoming Bank of America Securities Global Healthcare Conference could potentially provide a platform for Repligen to showcase its growth prospects and strategic initiatives, which might help in regaining investor confidence and stabilizing the stock price in the future.

05.04.2026 - RGEN Stock was up 5.6%

• Repligen Corporation reported impressive earnings results for the first quarter of 2026, with a significant revenue increase to $194.3 million and adjusted EPS of $0.48 per share, surpassing analyst estimates.
• The company's decision to divest its Polymem filtration business, launch a Transformation Office for margin expansion, and enter a new OEM partnership in China has likely boosted investor confidence in its growth potential.
• The increased stake in RGEN by institutional investors like Artemis Investment Management LLP and Conestoga Capital Advisors LLC further indicates positive sentiment and long-term belief in the company's performance and future prospects.
• Overall, the strong financial performance, strategic business decisions, and increased institutional investments have contributed to the bullish movement in Repligen's stock today.

05.04.2026 - RGEN Stock was up 5.2%

• Today's bullish movement in Repligen's stock is driven by the positive sentiment surrounding the company, supported by institutional investors increasing their holdings and the strong quarterly earnings report. The market appears to be responding positively to the company's performance and growth potential, resulting in an increase in the stock price.

14.04.2026 - RGEN Stock was down 5.6%

• Repligen's stock price fell by 5.4% to $107.41, aligning with a larger sector-wide sell-off impacting bioprocessing equipment suppliers, reflecting a trend that goes beyond company-specific factors.
• The concurrent declines seen among industry peers suggest a collective reassessment of positions within the sector, possibly driven by broader market sentiment or macroeconomic considerations.
• Despite internal transactions involving company insiders, like the Chief Product Officer's share withholding for tax purposes and a director's stock option exercise, these activities are unlikely to have directly caused the overall market decline in Repligen's stock.

22.05.2026 - RGEN Stock was down 4.0%

• The bearish movement in RGEN's stock price could be attributed to the softened enthusiasm for life sciences tools in the market, despite offering bullish Q1 guidance. This indicates a broader sentiment shift impacting the sector.
• Positive outlook on Repligen's future and anticipation of improved sentiment in Q2 may suggest that the current decline is a short-term market correction rather than a reflection of the company's long-term prospects.
• The technical analysis indicating a "Strong Buy" consensus may conflict with the bearish movement, highlighting potential discrepancies between market sentiment and underlying technical indicators.
• While RGEN's revenue breakdown shows a strong performance in filtration products and significant contributions from different regions, market dynamics and sector concerns seem to have overshadowed these positive aspects in today's trading session.